Table 7.

Acute effect of compounds 11, 17 and 35 on blood glucose levels in normal mice.

Test samples	Blood glucose concentration(mM)
	Dose (per os) mg/kg of bw	0h	1.5h	3h	5h	7h	9h
Control (vehicle)	–	10.9 ± 1.1	9.2 ± 0.3	8.6 ± 0.5	8.3 ± 0.3	7.8 ± 0.5	7.3 ± 0.4
			(−15.60)	(−21.10)	(−24.16)	(−28.75)	(−33.33)
Glibenclamide	10	9.8 ± 1.5	6.4 ± 1.4*	5.8 ± 0.8**	5.0 ± 1.4**	4.3 ± 0.6**	4.1 ± 0.7**
			(−34.58)	(−41.36)	(−49.15)	(−56.61)	(−58.31)
11	10	10.0 ± 0.7	9.1 ± 0.2	7.7 ± 0.6	6.6 ± 0.5	5.6 ± 0.4**	5.5 ± 1.2**
			(−15.27)	(−28.35)	(−38.01)	(−47.98)	(−48.91)
11	30	10.2 ± 1.2	8.7 ± 1.2	6.9 ± 1.1	5.9 ± 1.1*	5.2 ± 0.8**	5.1 ± 0.6**
			(−13.62)	(−30.90)	(−40.86)	(−47.84)	(−49.17)
11	100	10.4 ± 0.7	7.0 ± 1.1	5.9 ± 0.6*	4.8 ± 1.3**	4.7 ± 0.4**	4.3 ± 0.3**
			(−31.37)	(−42.16)	(−52.94)	(−54.25)	(−58.17)
17	10	10.6 ± 0.4	7.9 ± 0.7	6.9 ± 0.8	5.7 ± 0.7**	5.4 ± 0.5**	5.1 ± 0.4**
			(−23.96)	(−34.19)	(−45.37)	(−48.56)	(−51.12)
17	30	10.8 ± 0.3	8.4 ± 1.0	6.9 ± 0.9	5.3 ± 0.7**	5.3 ± 1.1**	4.5 ± 0.6**
			(−18.39)	(−33.55)	(−48.71)	(−48.71)	(−56.45)
17	100	10.4 ± 0.2	7.5 ± 1.2	6.3 ± 0.9*	5.2 ± 0.5**	4.7 ± 0.4**	4.3 ± 0.4**
			(−25.90)	(−37.71)	(−49.18)	(−53.44)	(−58.03)
35	10	10.8 ± 0.6	9.2 ± 0.6	8.2 ± 0.5	8.0 ± 0.4	7.4 ± 0.5	7.1 ± 0.3
			(−14.55)	(−24.15)	(−25.70)	(−31.27)	(−34.06)
35	30	10.5 ± 0.9	8.7 ± 1.0	7.2 ± 0.8	6.4 ± 1.0	5.8 ± 0.7**	5.9 ± 0.6
			(−17.72)	(−31.65)	(−39.24)	(−44.94)	(−44.30)
35	100	10.6 ± 0.4	8.7 ± 0.5	6.3 ± 1.0*	5.4 ± 0.6*	4.8 ± 0.6**	4.6 ± 0.7**
			(−18.18)	(−40.44)	(−49.22)	(−55.17)	(−57.05)

Each value is the mean ± SEM for six mice in each group.

^*p < 0.05 significantly different ANOVA followed by Dunnett’s t-test for comparison with respect to initial levels in each group.

% Variation of glycemia are in parentheses.